Investigational Drug Information for Azacytidine
✉ Email this page to a colleague
What is the drug development status for Azacytidine?
Azacytidine is an investigational drug.
There have been 252 clinical trials for Azacytidine.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2019.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Celgene Corporation.
There is one US patent protecting this investigational drug and twenty-five international patents.
Summary for Azacytidine
| US Patents | 1,528 |
| International Patents | 25,009 |
| US Patent Applications | 4,479 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 25 |
| Clinical Trial Progress | Phase 3 (2019-09-01) |
| Vendors | 97 |
Recent Clinical Trials for Azacytidine
| Title | Sponsor | Phase |
|---|---|---|
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | M.D. Anderson Cancer Center | Phase 2 |
| A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndro | M.D. Anderson Cancer Center | Phase 2 |
Clinical Trial Summary for Azacytidine
Top disease conditions for Azacytidine
Top clinical trial sponsors for Azacytidine
US Patents for Azacytidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Azacytidine | See Plans and Pricing | Heterocyclic compounds useful in the treatment of disease | Epigen Biosciences, Inc. (San Diego, CA) | See Plans and Pricing |
| Azacytidine | See Plans and Pricing | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | See Plans and Pricing |
| Azacytidine | See Plans and Pricing | Peptides and combination of peptides for use in immunotherapy against various tumors | IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE) | See Plans and Pricing |
| Azacytidine | See Plans and Pricing | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | Seattle Genetics, Inc. (Bothell, WA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Azacytidine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Azacytidine | Canada | CA2794266 | 2030-03-24 | See Plans and Pricing |
| Azacytidine | China | CN103037690 | 2030-03-24 | See Plans and Pricing |
| Azacytidine | China | CN105837411 | 2030-03-24 | See Plans and Pricing |
| Azacytidine | China | CN110386876 | 2030-03-24 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
